SEASTAR MEDICAL HOLDING CORP (ICU) Stock Price & Overview

NASDAQ:ICUUS81256L3024

Current stock price

4.31 USD
+0.75 (+21.07%)
At close:
4.2936 USD
-0.02 (-0.38%)
After Hours:

The current stock price of ICU is 4.31 USD. Today ICU is up by 21.07%. In the past month the price increased by 67.05%. In the past year, price decreased by -68.99%.

ICU Key Statistics

52-Week Range2.07 - 14.7
Current ICU stock price positioned within its 52-week range.
1-Month Range2.07 - 4.55
Current ICU stock price positioned within its 1-month range.
Market Cap
15.516M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-8.30
Dividend Yield
N/A

ICU Stock Performance

Today
+21.07%
1 Week
+54.48%
1 Month
+67.05%
3 Months
+63.82%
Longer-term
6 Months -33.55%
1 Year -68.99%
2 Years -96.41%
3 Years -99.20%
5 Years N/A
10 Years N/A

ICU Stock Chart

SEASTAR MEDICAL HOLDING CORP / ICU Daily stock chart

ICU Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ICU. When comparing the yearly performance of all stocks, ICU is a bad performer in the overall market: 71.33% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ICU Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ICU. While ICU seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ICU Earnings

On March 25, 2026 ICU reported an EPS of -0.8 and a revenue of 420.00K. The company beat EPS expectations (25.28% surprise) and beat revenue expectations (11.64% surprise).

Next Earnings DateMay 12, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.80
Revenue Reported420K
EPS Surprise 25.28%
Revenue Surprise 11.64%

ICU Forecast & Estimates

5 analysts have analysed ICU and the average price target is 9.18 USD. This implies a price increase of 112.99% is expected in the next year compared to the current price of 4.31.

For the next year, analysts expect an EPS growth of 59.54% and a revenue growth 54.99% for ICU


Analysts
Analysts80
Price Target9.18 (112.99%)
EPS Next Y59.54%
Revenue Next Year54.99%

ICU Groups

Sector & Classification

ICU Financial Highlights

Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -8.3. The EPS increased by 89.33% compared to the year before.


Income Statements
Revenue(TTM)1.23M
Net Income(TTM)-12.15M
Industry RankSector Rank
PM (TTM) N/A
ROA -85.82%
ROE -116.65%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%91.11%
Sales Q2Q%526.87%
EPS 1Y (TTM)89.33%
Revenue 1Y (TTM)814.07%

ICU Ownership

Ownership
Inst Owners2.21%
Shares3.60M
Float3.51M
Ins Owners2.53%
Short Float %4.78%
Short Ratio1.27

ICU Latest News, Press Relases and Analysis

About ICU

Company Profile

ICU logo image Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).

Company Info

IPO: 2021-01-26

SEASTAR MEDICAL HOLDING CORP

3513 Brighton Blvd, Suite 410

Denver COLORADO US

Employees: 19

ICU Company Website

ICU Investor Relations

Phone: 18444278100

SEASTAR MEDICAL HOLDING CORP / ICU FAQ

Can you describe the business of SEASTAR MEDICAL HOLDING CORP?

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).


Can you provide the latest stock price for SEASTAR MEDICAL HOLDING CORP?

The current stock price of ICU is 4.31 USD. The price increased by 21.07% in the last trading session.


What is the dividend status of SEASTAR MEDICAL HOLDING CORP?

ICU does not pay a dividend.


What is the ChartMill rating of SEASTAR MEDICAL HOLDING CORP stock?

ICU has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


On which exchange is ICU stock listed?

ICU stock is listed on the Nasdaq exchange.


What do analysts say about SEASTAR MEDICAL HOLDING CORP (ICU) stock?

5 analysts have analysed ICU and the average price target is 9.18 USD. This implies a price increase of 112.99% is expected in the next year compared to the current price of 4.31.


What is the ownership structure of SEASTAR MEDICAL HOLDING CORP (ICU)?

You can find the ownership structure of SEASTAR MEDICAL HOLDING CORP (ICU) on the Ownership tab.